Stockreport

Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age...

Roivant Sciences Ltd.  (ROIV) 
PDF - FDA PDUFA Action Expected in Q4 2024 - LONG BEACH, Calif. & BASEL, Switzerland, April 29, 2024 BUSINESS WIRE )--Dermavant Sciences, a biopharmaceutical company dedi [Read more]